Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Gerratana

Showing results (1-10 of 127) with videos related to

Pageof 13
Sort By:
Cancers|September 9, 2022
Liquid Biopsy, an Everchanging Balance between Clinical Utility and Emerging TechnologiesLinda Cucciniello, Lorenzo Gerratana, Fabio Puglisi
Breast Cancer Research and Treatment|October 7, 2023
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation?Rossana Roncato, Fabio Puglisi, Lorenzo Gerratana
Frontiers in Oncology|June 12, 2026
Editorial: Early detection, cancer interception, et al.: translating the multifaceted use of liquid biopsy to the management of early diseaseLetizia Pontolillo, Lorenzo Gerratana, Carolina Reduzzi
Frontiers in Genetics|August 26, 2022
Editorial: Cancer evolution: From biological insights to therapeutic opportunitiesAndrew A Davis, Lorenzo Gerratana, Marco Mina
Recenti Progressi in Medicina|January 19, 2016
[Complementary and alternative medicine in oncology]Claudia Bozza, Elisa Agostinetto, Lorenzo Gerratana, et al.
Cancer Treatment Reviews|August 9, 2022
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?Linda Cucciniello, Lorenzo Gerratana, Lucia Del Mastro, et al.
Frontiers in Cardiovascular Medicine|October 3, 2022
The puzzling clinical presentation of fluoropyrimidines cardiotoxicityLinda Cucciniello, Ettore Bidoli, Elda Viel, et al.
The Journal of Liquid Biopsy|March 3, 2025
Cellular residual disease (CRD) in early breast cancer -Expanding the concept of minimal residual disease monitoring?Mara S Serafini, Elisabetta Molteni, Eleonora Nicolò, et al.
Current Treatment Options in Oncology|July 1, 2019
Emerging Role of Genomics and Cell-Free DNA in Breast CancerLorenzo Gerratana, Andrew A Davis, Ami N Shah, et al.
Expert Opinion on Biological Therapy|January 17, 2017
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzleLorenzo Gerratana, Marta Bonotto, Claudia Bozza, et al.
Pageof 13

Showing results (1-10 of 127) with videos related to

Sort By:
Pageof 13
Cancers|September 9, 2022
Liquid Biopsy, an Everchanging Balance between Clinical Utility and Emerging TechnologiesLinda Cucciniello, Lorenzo Gerratana, Fabio Puglisi
Breast Cancer Research and Treatment|October 7, 2023
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation?Rossana Roncato, Fabio Puglisi, Lorenzo Gerratana
Frontiers in Oncology|June 12, 2026
Editorial: Early detection, cancer interception, et al.: translating the multifaceted use of liquid biopsy to the management of early diseaseLetizia Pontolillo, Lorenzo Gerratana, Carolina Reduzzi
Frontiers in Genetics|August 26, 2022
Editorial: Cancer evolution: From biological insights to therapeutic opportunitiesAndrew A Davis, Lorenzo Gerratana, Marco Mina
Recenti Progressi in Medicina|January 19, 2016
[Complementary and alternative medicine in oncology]Claudia Bozza, Elisa Agostinetto, Lorenzo Gerratana, et al.
Cancer Treatment Reviews|August 9, 2022
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?Linda Cucciniello, Lorenzo Gerratana, Lucia Del Mastro, et al.
Frontiers in Cardiovascular Medicine|October 3, 2022
The puzzling clinical presentation of fluoropyrimidines cardiotoxicityLinda Cucciniello, Ettore Bidoli, Elda Viel, et al.
The Journal of Liquid Biopsy|March 3, 2025
Cellular residual disease (CRD) in early breast cancer -Expanding the concept of minimal residual disease monitoring?Mara S Serafini, Elisabetta Molteni, Eleonora Nicolò, et al.
Current Treatment Options in Oncology|July 1, 2019
Emerging Role of Genomics and Cell-Free DNA in Breast CancerLorenzo Gerratana, Andrew A Davis, Ami N Shah, et al.
Expert Opinion on Biological Therapy|January 17, 2017
Pertuzumab and breast cancer: another piece in the anti-HER2 puzzleLorenzo Gerratana, Marta Bonotto, Claudia Bozza, et al.
Pageof 13